



LASOPERINTM SUPPORTS HEALTHY BRAIN PERFORMANCE & COGNITION*

Lasoperin[™] provides:



Supports Healthy Mental Acuity*

Clinically proven to support healthy brain performance & cognition*



Superior Formulation Compatibility

excellent as a stand alone or in a combination



Excellent Safety Profile

extensive in vivo and in vitro safety testing

Lasoperin™ is a standardized composition of Free-B-Ring Flavonoids and Flavans, clinically proven to offer short-term nutritional support for attention and focus and long-term support for cognition and memory.*

Product Profile

Plant Origin: Proprietary blend of standardized Free-B-Ring Flavonoids and Flavans

For more information on Lasoperin[™], please contact us at:


UNIGEN

2121 South State Street Suite 400 Tacoma, WA 98405 Ph: 253.274.7160

www.Unigen.net


This information is provided for scientific and educational purposes related to this ingredient.

^{*}These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.




Radial arm water maze (RAWM) study. After taking UP326 for 2 months, all dose groups showed significant improvement attenuation of agerelated memory impairments. 12 rats per group were used for each study.


Behav Neurol. 2016;2016:7240802.



Effects of Lasoperin on behavior and memory were also tested using contextual fear conditioning (normal freezing behavior to an electrical shock). *=p < 0.0001 versus young controls; †p < 0.0005 versus aged controls. 12 rats per group were used for each study.



Working memory speed RT median showed improvement from baseline to week 4. Relative to group A placebo, a significant improvement in working memory processing efficiency seen for groups B (UP326) in weeks 2 and 3 of treatment (* p < 0.05).



Working memory speed and reaction time standard deviation showed improvement from baseline to week 4. Relative to group A (placebo), a significant improvement in working memory processing efficiency seen for groups B (UP326) in week 3 of treatment (* p < 0.05).

